B*51:05 Count Matrix

B*51:05 Count Matrix</p

supplemental figure legend from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

supplemental figure legend</p

Supplementary 2 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Supplementary 2. In vivo efficacy of anti-CD22-vc-MMAE and anti-CD22-SPDB-DM4</p

Additional file 3: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

Figure S3. Phenotypic profiles of neoantigen-specific T cells in patients pre- and post atezolizumab treatment. Heatmaps show median expression intensities of all phenotypic markers probed in samples derived from the same patients. Markers are ordered based on unsupervised hierarchical clustering. (PDF 510 kb

Additional file 9: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

Table S6. Complete list of all tetramer positive hits detected for neoantigens and viral epitopes for all patients in the current study. (XLSX 12 kb

Additional file 4: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

Table S1. Patient characteristics and list of PBMC samples selected for the current analysis from the POPLAR trial. (XLSX 11 kb

Supplementary 4 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Supplementary 4. P-gp overexpressing BJAB.Luc cell line showed the similar resistance to anti-CD22-vc-MMAE</p

Supplementary 1 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Supplementary 1. In vivo efficacy of anti-CD22-vc-MMAE</p

Supplementary 3 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

Supplementary 3. Cell lines derived from xenograft tumors resistant to anti-CD22-vc-MMAE were resistance to anti-CD22-vc-MMAE</p

Additional file 5: of Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

Table S2. Tab 1, Number of neoantigen and viral specific tetramers generated for each patient sample. Tab 2, Complete list of peptides used to generate tetramers with their corresponding HLA alleles and predicted binding affinity. (XLSX 41 kb